<DOC>
	<DOCNO>NCT00697593</DOCNO>
	<brief_summary>To assess safety transition subject Raptiva therapy standard oral systemic phototherapy overlap Raptiva whilst taper initial systemic therapy phototherapy dose .</brief_summary>
	<brief_title>ChangE From Any Systemic psoriasiS therapY Raptiva</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Are least 18 year old . 2 . Have plaque psoriasis sPGA score least moderate severe time initiation previous systemic treatment . 3 . Are transition methotrexate , cyclosporine , retinoids , PUVA NBUVB initiate treatment Raptiva accord decision investigator accordance indication recommendation Raptiva Investigator Brochure , i.e . fail respond , contraindication intolerant systemic therapy . 4 . Agree participate study , disclose medical event investigator . The subject must willing able comply protocol requirement duration study . 5 . Have give write informed consent understand consent may withdraw time without prejudice future medical care . 6 . Women childbearing potential must use appropriate contraception treatment last study visit ( safety followup visit ) . For men , also mandatory practice contraception participation trial , exist data effect Raptiva spermatogenesis . 7 . Discontinuation investigational drug treatment 3 month prior study start per washout requirement previous protocol . No primary vaccination ( e.g. , tetanus , booster , influenza vaccine ) least 14 day prior first dose study drug.For purpose trial , woman childbearing potential define : `` All female subject puberty unless postmenopausal least two year , surgically sterile sexually inactive . '' 1 . Any contraindication Raptiva , accord Investigator Brochure , follow : Hypersensitivity Raptiva excipients . Subjects history malignancy . History active tuberculosis ( TB ) currently undergo treatment TB . Purified Protein Derivative ( PPD ) test chest Xray require highrisk subject . Subjects positive PPD ( due BCG vaccination ) chest Xray exclude . Subjects specific form psoriasis like guttate , erythrodermic pustular psoriasis sole predominant form psoriasis . Subjects immunodeficiency . 2 . Simultaneous participation another clinical trial . 3 . Subjects experience psoriasis exacerbation screen period . 4 . Subjects previously Raptiva treatment withdraw due lack efficacy adverse event . If withdrawal due another nondrug reason ( vaccination , infection ) subject include study . 5 . History hepatitis B , hepatitis C human immunodeficiency virus ( HIV ) . 6 . History thrombocytopenia , haemolytic anaemia clinically significant anaemia . 7 . Hepatic enzyme level =/ &gt; 3 time upper limit normal serum creatinine level =/ &gt; 2 time upper limit normal . 8 . Pregnant breastfeeding . 9 . Any medical condition ( prior exist ) , judgment investigator sponsor , could jeopardize subject 's safety follow exposure study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Efalizumab</keyword>
	<keyword>Chronic Plaque Psoriasis</keyword>
	<keyword>Transition systemic therapy Efalizumab</keyword>
</DOC>